SCHEMBL21138290

SCHEMBL21138290

CCCC(=O)N[C@H]1CO[C@H](COC(=O)c2ccccc2O)[C@@H](O)[C@@H]1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 4/20 0.42
▸ LMNA P02545 5/20 0.37
▸ TDP1 Q9NUW8 3/20 0.37
▸ CES2 O00748 1/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ TSHR P16473 2/20 0.36
▸ CDC25B P30305 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ CTDSP1 Q9GZU7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21138289 0.90 BCHE (0.37) BCHELMNACES2ALDH1A1HTT
SCHEMBL21058343 0.80 HK1 (0.40) BCHELMNATDP1L3MBTL1ALDH1A1
SCHEMBL21138213 0.80 LMNA (0.37) BCHELMNATDP1L3MBTL1ALDH1A1
SCHEMBL21137909 0.79 PYGB (0.41) L3MBTL1
SCHEMBL23104782 0.76 PYGB (0.39) L3MBTL1
SCHEMBL23104868 0.74 PYGB (0.37) TDP1L3MBTL1ALDH1A1KMT2AMAPT
SCHEMBL21138297 0.74 LMNA (0.35) BCHELMNATDP1L3MBTL1ALDH1A1
SCHEMBL23104924 0.72 PYGB (0.38) —
SCHEMBL24901989 0.72 PYGB (0.56) L3MBTL1GAA
SCHEMBL14621061 0.72 PYGB (0.56) L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA BCHE 794/4885LMNA 2632/4885TDP1 4185/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA BCHE 1090/4885LMNA 2743/4885TDP1 4136/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA BCHE 1090/4885LMNA 2743/4885TDP1 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback